Investigational drug · Phase 3
LNK01001
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Ankylosing Spondylitis, Atopic Dermatitis, Rheumatoid Arthritis.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
1 still active
All registered trials
6
Any phase or sponsor naming "LNK01001"
First trial start
2023
Dec 12, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LNK01001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Ankylosing Spondylitis
- Atopic Dermatitis
- Rheumatoid Arthritis
Approved drugs for the same conditions: Rheumatoid arthritis · Atopic dermatitis (eczema) · Ankylosing spondylitis · Immunology and inflammation · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "LNK01001" as an intervention, largest first.
- A Study of LNK01001 Capsule in Subjects With Active Rheumatoid Arthritis (COURAGE-RA)Pivotal-lookingCompleted
Lynk Pharmaceuticals Co., LtdIndustry
NCT06276998 · 430 participants · Start Dec 12, 2023 · Primary completion Aug 22, 2025
Drug: LNK01001; Placebo · For: Rheumatoid Arthritis
Sites: Beijing, China
- A Phase 3 Study of LNK01001 Capsule in Subjects With Moderate to Severe Atopic Dermatitis.Pivotal-lookingCompleted
Lynk Pharmaceuticals Co., LtdIndustry
NCT06277245 · 356 participants · Start Feb 6, 2024 · Primary completion Apr 18, 2025
Drug: LNK01001; Placebo · For: Atopic Dermatitis
Sites: Guangzhou, China
- A Study to Evaluate Efficacy and Safety of LNK01001 in Adults With Ankylosing SpondylitisPivotal-lookingRecruiting
Lynk Pharmaceuticals Co., LtdIndustry
NCT07237568 · 352 participants (planned) · Start Aug 29, 2025 · Primary completion Nov 2026
Drug: LNK01001; Placebo · For: Ankylosing Spondylitis
Sites: Beijing, China
- A Study of LNK01001 Capsule in Patients With Ankylosing SpondylitisPivotal-lookingCompleted
Lynk Pharmaceuticals Co., LtdIndustry
NCT06085534 · 177 participants · Start Jan 6, 2022 · Primary completion Dec 6, 2022
Drug: LNK01001; Placebo · For: Ankylosing Spondylitis
Sites: Beijing, China
- A Study of LNK01001 Capsule in Moderately to Severely Active Rheumatoid ArthritisPivotal-lookingCompleted
Lynk Pharmaceuticals Co., LtdIndustry
NCT06099535 · 156 participants · Start Nov 18, 2021 · Primary completion Dec 29, 2022
Drug: LNK01001 Dose A; LNK01001 Dose B and 1 more · For: Rheumatoid Arthritis
Sites: Beijing, China
- A Study of LNK01001 Capsule in Patients With Moderate to Severe Atopic DermatitisPivotal-lookingCompleted
Lynk Pharmaceuticals Co., LtdIndustry
NCT06085521 · 150 participants · Start Jan 26, 2022 · Primary completion Jun 14, 2023
Drug: LNK01001 Dose A; LNK01001 Dose B and 1 more · For: Atopic Dermatitis
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Ankylosing Spondylitis
- Jaktinib HydrochloridePhase 34 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Atopic Dermatitis, Ankylosing Spondylitis
- AK111Phase 32 trials
Akeso · Psoriasis, Skin Diseases, Ankylosing Spondylitis
- HS_SW01 cellsHS_SW01Phase 23 trials
Shenzhen Huishan Biotechnology Co., Ltd. · Ankylosing Spondylitis, Primary Ovarian Insufficiency (Poi), Systemic Sclerosis (SSc)
- vilamakitugXB2001, NatrunixPhase 22 trials
XBiotech, Inc. · Axial Spondyloarthritis, Ankylosing Spondylitis, r-axSpA
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.